Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Individualized prediction of lung-function decline in chronic obstructive pulmonary disease.

Zafari Z, Sin DD, Postma DS, Löfdahl CG, Vonk J, Bryan S, Lam S, Tammemagi CM, Khakban R, Man SFP, Tashkin D, Wise RA, Connett JE, McManus B, Ng R, Hollander Z, Sadatsafavi M.

CMAJ. 2016 Oct 4;188(14):1004-1011. doi: 10.1503/cmaj.151483. Epub 2016 Aug 2.

2.

Plasma pro-surfactant protein B and lung function decline in smokers.

Leung JM, Mayo J, Tan W, Tammemagi CM, Liu G, Peacock S, Shepherd FA, Goffin J, Goss G, Nicholas G, Tremblay A, Johnston M, Martel S, Laberge F, Bhatia R, Roberts H, Burrowes P, Manos D, Stewart L, Seely JM, Gingras M, Pasian S, Tsao MS, Lam S, Sin DD; Pan-Canadian Early Lung Cancer Study Group.

Eur Respir J. 2015 Apr;45(4):1037-45. doi: 10.1183/09031936.00184214. Epub 2015 Jan 22. Erratum in: Eur Respir J. 2016 Sep;48(3):962.

3.

Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling.

McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, Kong CY, Choi SE, Munshi VN, Han SS, van Rosmalen J, Pinsky PF, Moolgavkar S, de Koning HJ, Feuer EJ.

PLoS One. 2014 Jun 30;9(6):e99978. doi: 10.1371/journal.pone.0099978. eCollection 2014.

4.

Pro-surfactant protein B as a biomarker for lung cancer prediction.

Sin DD, Tammemagi CM, Lam S, Barnett MJ, Duan X, Tam A, Auman H, Feng Z, Goodman GE, Hanash S, Taguchi A.

J Clin Oncol. 2013 Dec 20;31(36):4536-43. doi: 10.1200/JCO.2013.50.6105. Epub 2013 Nov 18.

5.

Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.

Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, Riley TL, Commins J, Oken MM, Berg CD, Prorok PC.

J Natl Cancer Inst. 2011 Jul 6;103(13):1058-68. doi: 10.1093/jnci/djr173. Epub 2011 May 23.

6.

Secondhand smoke as a potential cause of chronic rhinosinusitis: a case-control study.

Tammemagi CM, Davis RM, Benninger MS, Holm AL, Krajenta R.

Arch Otolaryngol Head Neck Surg. 2010 Apr;136(4):327-34. doi: 10.1001/archoto.2010.43.

PMID:
20403847
7.

Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.

Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L.

Int J Cancer. 2009 Mar 1;124(5):1213-9. doi: 10.1002/ijc.24054.

8.

Factors associated with human small aggressive non small cell lung cancer.

Tammemagi CM, Freedman MT, Church TR, Oken MM, Hocking WG, Kvale PA, Hu P, Riley TL, Ragard LR, Prorok PC, Berg CD.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2082-9.

9.

Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes.

Tammemagi CM.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):31-6. Review.

PMID:
17218849
10.

Comorbidity and survival disparities among black and white patients with breast cancer.

Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D.

JAMA. 2005 Oct 12;294(14):1765-72.

PMID:
16219879
11.
12.

In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival.

Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P.

J Clin Epidemiol. 2004 Jun;57(6):597-609.

PMID:
15246128
13.

Smoking and lung cancer survival: the role of comorbidity and treatment.

Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P.

Chest. 2004 Jan;125(1):27-37.

PMID:
14718417
14.

Impact of comorbidity on lung cancer survival.

Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P.

Int J Cancer. 2003 Mar 1;103(6):792-802.

Supplemental Content

Loading ...
Support Center